The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

The majority of gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT, an HSP90 client protein. Further secondary resistance mutations within KIT limit clinical responses to tyrosine kinase inhibitors, such as imatinib. The dependence of KIT and its mutated forms on...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Smyth, Tomoko, Van Looy, Thomas, Curry, Jayne E., Rodriguez-Lopez, Ana M., Wozniak, Agnieszka, Zhu, Meijun, Donsky, Rachel, Morgan, Jennifer G., Mayeda, Mark, Fletcher, Jonathan A., Schöffski, Patrick, Lyons, John, Thompson, Neil T., Wallis, Nicola G.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2012
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3992119/
https://ncbi.nlm.nih.gov/pubmed/22714264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-11-1046
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים